Vaxil Bio Ltd.
Toronto Stock Exchange VenturesTotal Valuation
Vaxil Bio Ltd. carries a market capitalization of 507,331.00, placing it among publicly traded companies globally. Its enterprise value stands at -53,841.10, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 507,331.00 |
| Enterprise Value | -53,841.10 |
Share Statistics
Vaxil Bio Ltd. currently has 3.98M shares outstanding.
| Shares Outstanding | 3.98M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Vaxil Bio Ltd. trades at a trailing price-to-earnings ratio of 0.98.
| PE Ratio | 0.98 |
| PS Ratio | N/A |
| PB Ratio | -0.16 |
| P/TBV Ratio | 0.38 |
| P/FCF Ratio | -1.86 |
| P/OCF Ratio | -1.86 |
Financial Position
Vaxil Bio Ltd. maintains a current ratio of 16.92, meaning it holds 16.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 16.92 |
| Quick Ratio | 16.92 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 49.04 |
| Return on Invested Capital (ROIC) | -23.34 |
| Return on Capital Employed (ROCE) | -14.87 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Vaxil Bio Ltd.'s stock has declined approximately -7.5% over the past 52 weeks. The 50-day moving average sits at 0.22, while the 200-day moving average is 0.17.
| Beta (5Y) | N/A |
| 52-Week Price Change | -7.5% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.17 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -222,000.00, while operating income came in at -222,000.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -222,000.00 |
| Pretax Income | 476,000.00 |
| Net Income | 485,000.00 |
| EBITDA | -222,000.00 |
| EBIT | -222,000.00 |
| Earnings Per Share (EPS) | 0.15 |
Balance Sheet
Total book value stands at -2.99M, with working capital of 573,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 527,000.00 |
| Total Debt | N/A |
| Net Debt | -527,000.00 |
| Equity (Book Value) | -2.99M |
| Book Value Per Share | -0.95 |
| Working Capital | 573,000.00 |
Cash Flow
Vaxil Bio Ltd. produced -255,000.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -255,000.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -255,000.00 |
| FCF Per Share | -0.08 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -53.89 |
Stock Splits
Vaxil Bio Ltd.'s most recent stock split took place on May 15, 2025 with a 50:1 split ratio.
| Last Split Date | 5/15/2025 |
| Split Ratio | 50:1 |
Scores
Vaxil Bio Ltd. posts an Altman Z-Score of -12.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.84 |